FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Matzim LA Recall

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles,…

Teva Pharmaceuticals USA Inc · Parsippany, NJ

Risk level
Class II
Reported by FDA
Aug 10, 2022
Recall ID
D-1303-2022
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Matzim LA starting Jul 21, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1303-2022 on Aug 10, 2022. Reason: Failed Dissolution Specifications: below specification limits for dissolution. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications: below specification limits for dissolution.

Product description

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Lot numbers, UPCs & expiration codes

Lot 1411596A, Exp 09/22

Where it was sold

Nationwide in the USA and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1303-2022
Classification
Class II
Status
Terminated
Recall initiated
Jul 21, 2022
FDA report date
Aug 10, 2022
Quantity
5677 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA Inc

Original FDA data

Every field from FDA enforcement report D-1303-2022, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
90635
Address
400 Interpace Pkwy Bldg A
Code information
Lot 1411596A, Exp 09/22
Postal code
07054-1120
Report date
Aug 10, 2022
Product type
Drugs
Recall number
D-1303-2022
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA Inc
Product quantity
5677 bottles
Termination date
Apr 18, 2023
Reason for recall
Failed Dissolution Specifications: below specification limits for dissolution.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.
Distribution pattern
Nationwide in the USA and Puerto Rico
Recall initiation date
Jul 21, 2022
Center classification date
Aug 4, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1303-2022, published Aug 10, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls